GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (STU:RB0) » Definitions » Ending Cash Position

Regenxbio (STU:RB0) Ending Cash Position : €52.84 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regenxbio Ending Cash Position?

Regenxbio's Ending Cash Position for the quarter that ended in Sep. 2024 was €52.84 Mil.

Regenxbio's quarterly Ending Cash Position declined from Mar. 2024 (€105.81 Mil) to Jun. 2024 (€55.55 Mil) and declined from Jun. 2024 (€55.55 Mil) to Sep. 2024 (€52.84 Mil).

Regenxbio's annual Ending Cash Position declined from Dec. 2021 (€307.31 Mil) to Dec. 2022 (€93.44 Mil) and declined from Dec. 2022 (€93.44 Mil) to Dec. 2023 (€33.52 Mil).

Regenxbio Ending Cash Position Historical Data

The historical data trend for Regenxbio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Ending Cash Position Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.76 279.28 307.31 93.44 33.52

Regenxbio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.82 33.52 105.81 55.55 52.84

Regenxbio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Regenxbio's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=90.766+-57.248
=33.52

Regenxbio's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=53.876+-1.035
=52.84

Regenxbio Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Regenxbio's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenxbio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (STU:RB0) » Definitions » Ending Cash Position
Comparable Companies
INBX ADPT KYMR AMAM AKRO NVAX KURA VERV IMTX NAMS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RGNX:USA
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Website
https://www.regenxbio.com
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Headlines

No Headlines